Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Disease crawled date : 2021 - 10 - 26 save search
Teva and MODAG Announce Licensing Collaboration for Neurodegenerative Disease Drug Candidate
Published: 2021-10-26 (Crawled : 21:00) - biospace.com/
TEVA | $13.23 -0.53% -0.23% 13M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
disease neurodegenerative collaboration oda drug license
Secarna Pharmaceuticals and Denali Therapeutics Expand Strategic Partnership for the Discovery and Development of Novel ASO Therapeutics in the Field of CNS Diseases
Published: 2021-10-26 (Crawled : 18:00) - biospace.com/
DNLI | $17.84 -2.3% -2.3% 990K
|
Health Technology
|
| O: -0.15%
H: 0.0%
C: 0.0%
disease partnership
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare Diseases
Published: 2021-10-26 (Crawled : 17:00) - biospace.com/
SELB M | $0.8812 -8.0% 2.12% 0
|
Health Technology
|
| O: 1.68%
H: 0.0%
C: 0.0%
disease treatment partnership bioscience rare
BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107’s Pro-motoric Activity in Parkinson’s Disease
Published: 2021-10-26 (Crawled : 14:15) - biospace.com/
BIVI | $0.4927 -3.49% 4.93% 1.3M
|
Health Technology
|
| O: 6.04%
H: 0.0%
C: 0.0%
disease fda phase 2 parkinson trials trial
Vertex and Mammoth Biosciences Announce Collaboration to Develop In Vivo Gene-Editing Therapies for Serious Diseases
Published: 2021-10-26 (Crawled : 14:00) - biospace.com/
VRTX | $397.48 0.24% 0.23% 1.4M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
disease collaboration therapy
4D Molecular Therapeutics Reports Interim Results from the 4D-310 Phase 1/2 Clinical Trial in Patients with Fabry Disease and Provides Clinical Data Update from the 4D-110 Phase 1/2 Clinical Trial in Patients with Choroideremia
Published: 2021-10-25 (Crawled : 00:00) - biospace.com/
FDMT | $26.25 -0.38% -0.42% 610K
|
Health Technology
|
| O: 0.22%
H: 2.43%
C: 1.48%
disease phase 1 results molecular trial phase 2 phase 3
Gainers vs Losers
| 47% | 53% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.74 79.7% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4004 45.07% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.54 29.48% 22.88% 3.9M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.